GlassScriptPhysician profile
Katherine Torres
NPI 1780332338
$12,116.17
in general payments reported to CMS, 2019-2025
47 companies · $1,629 in 2025
The $1,629 reported for 2025 was more than what 90% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $2,545 · 2023: $3,787 · 2024: $4,155 · 2025: $1,629.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,245 · Education: $325.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,245.36 |
| Education | $325.43 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $3,003.37 | 2022-2025 | Enbrel, Otezla, Evenity |
| Novartis Pharmaceuticals Corporation | $1,042.25 | 2022-2025 | |
| Astrazeneca Pharmaceuticals LP | $836.95 | 2022-2025 | Saphnelo, Tezspire, Airsupra |
| Glaxosmithkline, LLC. | $712.54 | 2023-2025 | Benlysta, Nucala, Arexvy |
| Ucb, INC. | $688.03 | 2022-2024 | Cimzia, Bimzelx |
| Actelion Pharmaceuticals US, INC. | $657.70 | 2023-2025 | Uptravi, Opsumit |
| Boehringer Ingelheim Pharmaceuticals, INC. | $619.40 | 2022-2025 | Ofev, Cyltezo |
| Takeda Pharmaceuticals U.S.A., INC. | $540.55 | 2023-2025 | Hyqvia, Glassia, Cuvitru |
| Mallinckrodt Hospital Products INC. | $533.44 | 2022-2024 | Acthar |
| Abbvie INC. | $510.64 | 2023-2025 | |
| Kyowa Kirin, INC. | $216.39 | 2023-2024 | Crysvita |
| Pfizer INC. | $207.96 | 2023-2025 | |
| United Therapeutics Corporation | $207.12 | 2024-2025 | Tyvaso, Tyvaso, Remodulin |
| Horizon Therapeutics Plc | $205.31 | 2022-2023 | Krystexxa |
| Ani Pharmaceuticals, INC. | $202.95 | 2022-2024 | Purified Cortrophin Gel |
Show all 47 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $174.19 | 2022-2025 | Taltz, Zepbound |
| Electromed, INC. | $141.82 | 2024-2025 | Smartvest |
| Regeneron Healthcare Solutions, INC. | $140.41 | 2024-2025 | Dupixent |
| Alexion Pharmaceuticals, INC. | $106.88 | 2022-2023 | Strensiq |
| Verona Pharma, INC. | $100.84 | 2025 | Ohtuvayre |
| Sanofi-Aventis U.S. LLC | $99.99 | 2024 | |
| Merck Sharp & Dohme LLC | $98.54 | 2024-2025 | Winrevair, Capvaxive |
| Aurinia Pharma U.S., INC. | $96.01 | 2022-2024 | Lupkynis |
| Janssen Biotech, INC. | $95.88 | 2022-2024 | Tremfya, Simponi, Remicade |
| Radius Health, INC. | $90.78 | 2022-2024 | Tymlos |
| Paratek Pharmaceuticals, INC. | $58.66 | 2025 | Nuzyra |
| Insmed, INC. | $56.28 | 2025 | Arikayce |
| Optinose US, INC. | $55.90 | 2025 | |
| Genzyme Corporation | $55.89 | 2024-2025 | |
| Vifor Pharma, INC. | $51.60 | 2024-2025 | Zemaira |
| Grifols USA, LLC | $47.93 | 2025 | Prolastin-C Liquid |
| Fresenius Kabi USA, LLC | $47.82 | 2023-2024 | Idacio |
| Baxter Healthcare | $44.91 | 2024-2025 | Hillrom - Vest System Model 105 Home Care |
| Kiniksa Pharmaceuticals, LTD. | $43.63 | 2022-2023 | Arcalyst |
| E.R. Squibb & Sons, L.L.C. | $42.77 | 2024 | Orencia |
| Recordati_rare_diseases_inc. | $42.61 | 2024 | Sylvant |
| Jazz Pharmaceuticals INC. | $34.88 | 2024 | |
| Ars Pharmaceuticals Operations, INC. | $28.53 | 2025 | Neffy |
| Philips North America LLC | $23.91 | 2024 | (Ak6) Vest Therapy |
| Sobi, INC | $23.00 | 2024 | |
| Octapharma USA, INC. | $22.39 | 2024 | Octagam Immune Globulin (Human) |
| Mylan Institutional INC. | $22.20 | 2023 | Hulio |
| Csl Behring | $21.47 | 2025 | Hizentra |
| Almatica Pharma LLC | $18.70 | 2024 | Teriparatide |
| Alvogen INC | $15.54 | 2022 | |
| Idorsia Pharmaceuticals US INC | $14.25 | 2023 | Quviviq |
| Organon LLC | $13.36 | 2023 | Hadlima, Renflexis |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Katherine Torres listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.